Cutaquig Indication Now Includes Treatment of Pediatric Patients
October 27, 2021Scemblix Approved to Treat Chronic Myeloid Leukemia
October 29, 2021October 29, 2021 – VuityTM (pilocarpine HCI ophthalmic solution) 1.25% has been approved to treat presbyopia. It is the first and only eye drop to receive U.S. FDA approval for this indication.
- Presbyopia is also known as age-related farsightedness and occurs naturally as the eye's lens loses the ability to focus on objects at near and intermediate distances. Treatments include eyeglasses (often non-prescription), contact lenses, and surgical correction.
- Vuity uses the eye's ability to reduce pupil size to improve focus on objects at near and intermediate distances without affecting the eye’s ability to focus on faraway objects.
- Recommended dosing is one drop in each eye daily. Vuity should be administered at least five minutes before or after administering any other topical eye product the patient may be taking.
- Allergan, the manufacturer, has launched Vuity at a wholesale acquisition cost (WAC) of $73.49 per 2.5mL bottle.